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Abstract 
 
Purpose: To investigate if the application of Blephagel, an eyelid cleansing gel, causes 
subjective and/or objective cooling effects by measuring ocular symptomology and 
temperature. 
Methods: Twenty-five healthy subjects underwent baseline non-invasive temperature 
measurements on the closed upper eyelid (centrally, nasally, and temporally) and ocular 
surface temperature (OST) on both eyes using an infrared camera. A standard application of 
Blephagel was then applied to the closed upper eyelid and eyelashes with a sterile cotton-
wool to one eye selected at random. Temperature measures were then repeated on both eyes 
after 30-60, 120-150, and 180-210 seconds. At each interval, subjects rated the comfort and 
any cooling sensation of each eye on a 0-10 scale.  
Results: After application of the gel, there was a significant difference in temperature at all 
locations on the eyelid between the test and control eyes over time (F=9.322, p<0.001). Post 
hoc analysis revealed this was significant from 30-60 second interval (36.3 ± 1.1°C versus 
37.2 ± 0.7°C; p<0.001) and the 120-150 seconds interval (36.8 ± 0.8°C versus 37.2 ± 0.6°C; 
p<0.001). There was no significant variation between the OST locations over time (F=3.350, 
p=0.07).  With respect to symptoms, there was a significant increase in cooling sensation in 
the test eye compared to the control eye over time (F=10.438, p<0.001), that remained 
throughout the experiment.  
Conclusions: Blephagel produces a reduction in temperature of the eyelids that is 
accompanied with a subjective cooling sensation.  
Abstract word count: 233  
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Main Text 
 
INTRODUCTION 1 
Eyelid cleansing has been established as an effective long-term method to treat anterior 2 
blepharitis by removing debris from the eyelid margin [1, 2]. Typically, this process involves 3 
application of a warm compress [2], or solution impregnated wipes/eye pads [3, 4, 5]. 4 
However, compliance with treatment regimens is variable, particularly with combination 5 
therapies [6].  More recently, an eyelid cleansing gel, “Blephagel” (Thea Pharmaceuticals, 6 
Keele, UK), has been developed that may provide a cooling sensation and thus additional 7 
symptomatic relief, which may be beneficial when eyelids are inflamed. Indeed, inflammation 8 
is reflected by local increases in skin temperature due to blood vessel dilatation and increased 9 
blood flow as measured with infrared thermal imaging [7], including the ocular surface as 10 
observed in dry eye, scleritis, anterior uveitis, and Grave’s ophthalmopathy [7, 8, 9]. Hence 11 
reducing ocular temperature may help relieve the signs and symptoms of blepharitis. The aim 12 
of this study was to therefore investigate whether any subjectively reported cooling effect is 13 
experienced and if this could be measured objectively, in healthy subjects. 14 
 15 
MATERIALS & METHODS 16 
The study was designed as a contralateral eye comparison (one test eye, one control eye). 17 
The study was reviewed and approved by the Institutional Review Board; and complied with 18 
the Declaration of Helsinki and the UK Data Protection Act. All subjects were enrolled with 19 
written informed consent following a description of the study and any potential risks. 20 
 21 
Experimental Protocol 22 
Subjects (n=25) were recruited from Aston University. Inclusion criteria required subjects to 23 
be ≥18 years old, with no active ocular (confirmed with a slit lamp biomicroscope examination) 24 
or systemic disease, no medications, or contact lens wear. They were masked to the premise 25 
of the study.  26 
Baseline temperature was measured on the closed upper eyelid centrally and along the upper 27 
eyelid margin (centrally, nasally, and temporally). Ocular surface temperature (OST) was also 28 
measured on the cornea (centrally) and of the bulbar conjunctiva (nasally and temporally) on 29 
both eyes using an infrared camera (Thermo Tracer TH7102; NEC Corporation, Tokyo, Japan) 30 
by measuring the average temperature within 5mm2 area at each location, where a series of 31 
digital markers were used to ensure the same area was measured per subject [10]). Room 32 
temperature was consistent (mean 22.1±0.3°C, measured daily from digital thermometer in 33 
thermostat regulated room) and air flow minimised (doors closed with no windows) during data 34 
collection. 35 
A single unit dose (one pump) of cleansing gel from the dispenser was then first applied to a 36 
sterile cotton-wool pad and then to the closed upper eyelid and along the eyelash line to one 37 
eye (selected at random via number generator). The researcher was masked as to the chosen 38 
test eye.  39 
Closed eyelid temperatures and OST measures were then repeated on both eyes after 30-60, 40 
120-150, and 180-210 seconds post application. Subjects were asked to rate the comfort and 41 
any cooling sensation of each eye on separate 0-10 scales for each symptom (0=poor 42 
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comfort/no cooling sensation; 10=excellent comfort/strong cooling sensation) at the same time 43 
intervals.  44 
Subjects were instructed to keep both eyes closed for the duration of the study, unless OST 45 
was being measured. 46 
 47 
Statistical Analysis 48 
Data was assessed for normality using the Kolmogorov-Smirnov test. Temperature changes 49 
over time were evaluated by repeated measures analysis of variance (ANOVA), and where 50 
statistical significance was identified (p<0.05), post hoc analysis was performed using paired 51 
t tests. 52 
 53 
RESULTS 54 
All 25 subjects (64% female; mean age (±1 standard deviation) = 20.8±1.3 years) completed 55 
the study without complications, and no adverse events or additional symptoms reported. 56 
 57 
Temperature on Closed Eyelids 58 
 59 
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 61 
 62 
Figure 1: Mean temperature ±1 standard deviation (°C) at each closed eyelid location over 63 
time for test and control eyes. * = statistically significant difference (p<0.05) between test 64 
and control eyes as determined by post-hoc analysis. 65 
 66 
At baseline, there was no (statistically) significant difference in temperature between the eyes 67 
at the same locations (Figure 1). After application of the gel, there was a statistically significant 68 
difference in temperature at all locations between the test and control eyes over time (F=9.322, 69 
p<0.001). The mean temperature across the entire eyelid surface reduced in the test eye, with 70 
post hoc analysis revealing this was significant from 30-60 second interval (36.3 ± 1.1°C 71 
versus 37.2 ± 0.7°C; p=0.00) to the 120-150 seconds interval (36.8 ± 0.8°C versus 37.2 ± 72 
0.6°C; p=0.00); after 180-210 seconds there was no significant difference in mean eyelid 73 
temperature across the closed eyelid surface between test and control eyes (37.1 ± 0.7°C 74 
versus 37.2 ± 0.6°C; p=0.06). However, the temperature of the temporal location of the test 75 
eye was not significantly different compared to the control eye between 120-150 seconds post 76 
application (p=0.42).  77 
Within eye comparisons show no significant change in temperature over time at any eyelid 78 
location in the control eye (F=2.076, p=0.136); but a significant change in temperature over 79 
time was observed in the test eye at all eyelid locations (F=9.902, p=<0.001). This temperature 80 
reduction was greatest between baseline and the 30-60 second interval, where temporal 81 
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reduced by 0.5°C (p=0.003), central by 0.7°C (p<0.001), and upper by 1.1 °C (p<0.001), except 82 
for the nasal location which was not significantly reduced compared to baseline in the test eye 83 
(p=0.62). This difference compared to baseline in the test eye was no longer significant after 84 
the 120-150 second interval for all locations. 85 
 86 
Temperature on Ocular Surface 87 
 88 
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 90 
Figure 2: Mean temperature ±1 standard deviation (°C) at each ocular surface location over 91 
time for test and control eyes. * = statistically significant difference (p<0.05) between test 92 
and control eyes as determined by post-hoc analysis.  93 
 94 
At baseline, there was no statistically significant difference in temperature between the same 95 
locations of the test and control eye (Figure 2). Although there was significant differences 96 
between the locations at each time interval per eye (F=50.916, p<0.001), these did not vary 97 
at the same locations between test and control eyes over time (F=3.350, p=0.07); except for 98 
the nasal location after 30-60 seconds (Figure 2;0.26°C cooler on test compared to control 99 
eye). Within eye comparisons also demonstrate no significant difference in temperature over 100 
time for control eyes (F=0.559, p=0.64) and test eyes (F=2.966, p=0.10) at all locations. 101 
 102 
Symptoms 103 
 104 
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 105 
Figure 3: Mean (±1 standard deviation) comfort and cooling sensation scores over time for 106 
text and control eyes. * = statistically significant difference between test and control eyes as 107 
determined by post-hoc analysis. 108 
 109 
There was no statically significant difference in comfort sensation between the test and control 110 
eyes at baseline (p=0.75) and over time (F=0.862, p=0.44). Within eye comparisons also 111 
demonstrated no significant difference in comfort over time for the control eye (F=0.279, 112 
p=0.84) and test eye (F=0.162, p=0.69). 113 
For the cooling sensation, at baseline there was no statistically significant difference between 114 
the test compared to the control eye (Figure 3; p=0.11). However, after the application of the 115 
gel there was a statistically significant increase in cooling sensation in the test eye compared 116 
to the control eye over time (F=10.438, p<0.001). Post hoc analysis reveals that this cooling 117 
sensation remained through the course of the experiment between the test and control (Table 118 
3), but the effect tapered significantly over time in the test eye (30-60 versus 120-150 p=0.01; 119 
120-150 versus 180-210 p=0.04). Within eye comparisons show the control eye remained 120 
unchanged with respect to cooling sensation over time (F=0.359, p=0.98), whereas for the test 121 
eye this was significant compared to baseline at all time intervals (F=9.830, p=<0.001). 122 
 123 
DISCUSSION 124 
The eyelid cleansing gel (Blephagel) produced a statistically significant reduction in 125 
temperature across the eyelid surface and margin, by approximately 1°C (actual 0.97°C) in 126 
the test eye compared to the control eye after 30-60 seconds post application. This reduction 127 
in temperature remained statistically significant up to 120-150 seconds (2 to 2.5 minutes) 128 
between the test and control eye, albeit at a smaller difference (0.33°C). This reduction in 129 
temperature is accompanied by a statistically significant increase in subjective cooling 130 
sensation between the test and control eyes, peaking at a score of 4.9 out of 10 after 30-60 131 
seconds. This effect was sustained for the duration of the experiment, suggesting the cooling 132 
sensation remains through to 180-210 (3 to 3.5 minutes); despite being no statistically 133 
significant difference in temperature between test and control eyes at any eyelid location at 134 
the 180-210 interval.   135 
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The gel produces a small effect on temperature of the ocular surface, with only the nasal 136 
bulbar conjunctiva decreasing significantly- this was not unexpected due to the direct 137 
application to the eyelid skin only to reflect the anatomical location where anterior blepharitis 138 
presents. However, cooling effects on the ocular surface (cornea and conjunctiva) have been 139 
reported following application of a gel mask on the closed eyelids in active allergic 140 
conjunctivitis [10] – here, the gel mask was applied for 5 minutes and was considerably cooler 141 
as it was refrigerated (to 2-4°C), whereas no such prior cooling was applied in this study. In 142 
this study by Bilkhu et. al (2014), the cooling effect was associated with improvement in ocular 143 
symptoms of allergic inflammation and reduction of conjunctival hyperaemia, likely due to 144 
induced vasoconstriction and subsequent reduced conjunctival blood flow [10].  Other studies 145 
have reported lowering of ocular surface temperature in eyes with scleritis and Grave’s 146 
ophthalmopathy following topical steroid therapy, which was associated with improvements in 147 
signs and symptoms [9, 11]. Therefore, the cooling effect produced by the gel may help 148 
improve signs of inflammation in blepharitis by inducing vasoconstriction. Moreover, the 149 
application/removal process of an eyelid cleansing gel can help remove any crusting/debris 150 
than often presents in anterior blepharitis [1, 2]. Much like solution impregnated eyelid wipes, 151 
this simple treatment method may help serve to aid compliance particularly in light of the 152 
concurrent cooling sensation [3, 4, 5], given that treatments with no immediate effect can lead 153 
to patient disengagement [12].  154 
Limitations of the study were due to the open-label design where subjects were aware which 155 
eye the gel is applied and thus prone to overestimating subjective reports on comfort/cooling 156 
(subject bias). This may explain the persistent cooling sensation after 180 seconds while the 157 
temperature differential between the test and control eyes was insignificant. In addition, 158 
subjects were healthy volunteers with no active eye disease – although the results cannot 159 
extend to actual anterior blepharitis sufferers, given the inflammatory nature of this condition 160 
the observed cooling effect in the present study may help improve symptoms during active 161 
episodes, which can include burning and gritty sensation of the eyelids [13]. Randomised, 162 
active-controlled (i.e. test product vs test vehicle) masked trials in patients with confirmed 163 
anterior blepharitis are therefore required to investigate clinical efficacy of Blephagel while 164 
negating subject and experimenter bias. The use of healthy subjects is very likely to explain 165 
the lack of any treatment effect on comfort, where baseline levels were unsurprisingly high. 166 
 167 
CONCLUSIONS 168 
Application of Blephagel produces a statistically significant reduction in temperature of the 169 
eyelid surface that is accompanied by subjective cooling sensation, which may persist beyond 170 
objective temperature changes. These effects may help relieve burning and gritty symptoms 171 
frequently reported in anterior blepharitis; in addition to removing any debris/crusting of the 172 
eyelashes through the application and removal process. Further study with robust clinical trial 173 
design is required to determine treatment effects in anterior blepharitis patients.  174 
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